Asset-Focused Funding
This article was originally published in Start Up
Executive Summary
A handful of early-stage VCs think they can generate better returns building and selling individual products, rather than companies.
You may also be interested in...
PanGenetics' NGF Antibody Sale Illustrates Index's Asset-Focused Strategy
The $170 million up-front that Abbott Laboratories ponied up for PanGenetics BV's Phase I PG110 anti-nerve growth factor antibody would rank as the largest down-payment ever for a Phase I project. But even though at first glance the mid-November deal resembles an alliance, it is in fact the acquisition of part of PanGenetics itself, and reveals founding investor Index Ventures' intriguing asset-focused strategy.
PanGenetics' NGF Antibody Sale Illustrates Index's Asset-Focused Strategy
The $170 million up-front that Abbott Laboratories ponied up for PanGenetics BV's Phase I PG110 anti-nerve growth factor antibody would rank as the largest down-payment ever for a Phase I project. But even though at first glance the mid-November deal resembles an alliance, it is in fact the acquisition of part of PanGenetics itself, and reveals founding investor Index Ventures' intriguing asset-focused strategy.
UK Antibiotics Play Novacta Wins £13.1 million, mostly from Celtic Pharma
Funds should allow Novacta Biosystems to take three peptide-based ‘lantibiotics' programs through to proof-of-efficacy and secure a licensing deal
Need a specific report? 1000+ reports available
Buy Reports